Core Points - Lifecore Biomedical, Inc. has granted a restricted stock unit (RSU) award for 15,000 shares and stock options for 30,000 shares to a newly hired employee as part of its Equity Inducement Plan [1][2] - The RSUs will vest on the third anniversary of the grant date, while the stock options will vest one-third on the first anniversary and the remaining shares monthly thereafter, subject to continued employment [3] Company Overview - Lifecore Biomedical is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and partners with global and emerging biopharmaceutical and biotechnology companies [4]

Company Overview - Sutro Biopharma, Inc. is focused on the discovery and development of precisely designed cancer therapeutics, particularly antibody drug conjugates (ADCs) [7] - The company is advancing a robust early-stage pipeline of novel exatecan-based and dual-payload ADCs, supported by high-value collaborations and industry partnerships [7] Leadership Appointment - Greg Chow has been appointed as Chief Financial Officer (CFO) effective June 2, 2025, bringing over 25 years of executive leadership experience in corporate finance, capital markets, and drug development operations [1][2] - Chow's previous roles include Chief Financial and Business Officer at NodThera, CFO at Freenome Holdings, and CFO at Frontier Medicines, where he successfully executed significant financing rounds [2][3] Financial Strategy and Goals - The leadership of Greg Chow is expected to enhance financial discipline, operational efficiency, and capital strategy, positioning the company to achieve key clinical milestones [2] - Chow expressed enthusiasm about joining Sutro, highlighting the company's unique position in ADC innovation and its powerful cell-free technology platform for drug discovery [2] Inducement Grants - Sutro has granted Greg Chow a restricted stock unit award for 100,000 shares and a non-qualified option to purchase 275,000 shares under the 2021 Equity Inducement Plan [4][5] - The option will have an exercise price equal to the closing price of Sutro's common stock on the appointment date, with vesting schedules for both the restricted stock and option awards [6]